Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

Sandhoff disease is a severe neurodegenerative glycosphingolipid (GSL) lysosomal storage disorder, currently without treatment options. One therapeutic approach under investigation is substrate reduction therapy (SRT). By partially inhibiting GSL biosynthesis, the impaired rate of GSL catabolism is...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Andersson, U, Smith, D, Jeyakumar, M, Butters, T, Borja, M, Dwek, R, Platt, F
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2004

Παρόμοια τεκμήρια

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
ανά: Ulrika Andersson, κ.ά.
Έκδοση: (2004-08-01)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
ανά: Jeyakumar, M, κ.ά.
Έκδοση: (2004)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
ανά: Andersson, U, κ.ά.
Έκδοση: (2000)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
ανά: Baek, R, κ.ά.
Έκδοση: (2004)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
ανά: Baek, R, κ.ά.
Έκδοση: (2008)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
ανά: Platt, F, κ.ά.
Έκδοση: (2003)

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
ανά: Jeyakumar, M, κ.ά.
Έκδοση: (2001)

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
ανά: Kasperzyk, J, κ.ά.
Έκδοση: (2004)

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
ανά: Kasperzyk, J, κ.ά.
Έκδοση: (2004)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
ανά: Baek, R, κ.ά.
Έκδοση: (2005)

MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.
ανά: Lowe, J, κ.ά.
Έκδοση: (2005)

Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat
ανά: Lachmann, R, κ.ά.
Έκδοση: (2006)

Analysis of stored oligosaccharides in a mouse model of a glycolipid storage (Sandhoff) disease
ανά: Awan, F, κ.ά.
Έκδοση: (2003)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
ανά: Elliot-Smith, E, κ.ά.
Έκδοση: (2008)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
ανά: Pelled, D, κ.ά.
Έκδοση: (2003)

Beneficial effects of acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff disease
ανά: Kaya, E, κ.ά.
Έκδοση: (2020)

New developments in treating glycosphingolipid storage diseases.
ανά: Platt, F, κ.ά.
Έκδοση: (2005)

Substrate reduction therapy
ανά: Platt, F, κ.ά.
Έκδοση: (2007)

Substrate reduction therapy.
ανά: Platt, F, κ.ά.
Έκδοση: (2008)

Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
ανά: Rountree, J, κ.ά.
Έκδοση: (2009)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
ανά: Denny, C, κ.ά.
Έκδοση: (2010)

Infantile Sandhoff's disease
ανά: K Sass, κ.ά.
Έκδοση: (2009-08-01)

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
ανά: Jeyakumar, M, κ.ά.
Έκδοση: (2002)

Storage solutions: treating lysosomal disorders of the brain.
ανά: Jeyakumar, M, κ.ά.
Έκδοση: (2005)

An inducible mouse model of late onset Tay-Sachs disease.
ανά: Jeyakumar, M, κ.ά.
Έκδοση: (2002)

Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease.
ανά: Richardson, K, κ.ά.
Έκδοση: (2016)

Efficacy of a Bicistronic Vector for Correction of Sandhoff Disease in a Mouse Model
ανά: Evan Woodley, κ.ά.
Έκδοση: (2019-03-01)

Dysregulation of the NLRP3 Inflammasome and Promotion of Disease by IL-1β in a Murine Model of Sandhoff Disease
ανά: Nick Platt, κ.ά.
Έκδοση: (2025-01-01)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
ανά: te Vruchte, D, κ.ά.
Έκδοση: (2010)

An Inducible Mouse Model of Late Onset Tay–Sachs Disease
ανά: Mylvaganam Jeyakumar, κ.ά.
Έκδοση: (2002-08-01)

Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
ανά: Andersson, U, κ.ά.
Έκδοση: (2004)

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
ανά: Platt, F, κ.ά.
Έκδοση: (2001)

Pharmacological impairment of acrosome formation and sperm head morphogenesis reveals essential role of glycosphingolipids in spermiogenesis
ανά: van der Spoel, A, κ.ά.
Έκδοση: (2002)

Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
ανά: Karen M Ashe, κ.ά.
Έκδοση: (2011-01-01)

Decrease in Myelin-Associated Lipids Precedes Neuronal Loss and Glial Activation in the CNS of the Sandhoff Mouse as Determined by Metabolomics
ανά: Emmanuelle Lecommandeur, κ.ά.
Έκδοση: (2020-12-01)

Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation.
ανά: Mellor, H, κ.ά.
Έκδοση: (2003)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
ανά: Jeyakumar, M, κ.ά.
Έκδοση: (2003)

Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of Sandhoff disease.
ανά: Yasuhiro Ogawa, κ.ά.
Έκδοση: (2013-01-01)

Abnormal differentiation of Sandhoff disease model mouse-derived multipotent stem cells toward a neural lineage.
ανά: Yasuhiro Ogawa, κ.ά.
Έκδοση: (2017-01-01)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
ανά: Priestman, D, κ.ά.
Έκδοση: (2008)